Regeneron/Sanofi press release on Praluent approval and pricing

Regeneron/Sanofi press release on Praluent approval and pricing The document is a standard pharmaceutical promotional release describing clinical trial results, pricing, and patient assistance programs. It contains no allegations, financial flows, or connections to high‑profile officials or controversial actions, offering no actionable investigative leads. Key insights: Details of Phase 3 ODYSSEY trial efficacy and safety data for Praluent (alirocumab).; Wholesale Acquisition Cost (WAC) disclosed at $40 per day.; Patient assistance and co‑pay support programs outlined.